Shares of Hims & Hers Health (HIMS) skyrocketed more than 44% during premarket trading Monday following a Bloomberg report indicating Novo Nordisk intends to distribute its weight-loss medications via the Hims platform.
Novo Nordisk $NVO and Hims & Hers $HIMS end their legal feud and will sell obesity drugs together, per Bloomberg.
Partnership expected to be announced as soon as Monday.
HIMS stock is up 41% After hours….wow pic.twitter.com/fxvCnTSuei— Robert Fekete (@rokajoska) March 7, 2026
According to the report, a formal announcement may be released as early as Monday. The revelation propelled HIMS shares dramatically higher, while Novo’s Copenhagen-traded shares advanced approximately 1%.
Hims & Hers Health, Inc., HIMS
The surge represents a dramatic reversal for shares that had already tumbled roughly 51% year-to-date prior to Monday’s rally.
Under the arrangement, Novo’s obesity medications — encompassing products associated with its Ozempic and Wegovy franchises — would become available directly through the Hims platform. This marks a significant pivot considering the contentious relationship between the companies in recent months.
Novo initiated litigation against Hims in February following the telehealth firm’s introduction of a competing version of Novo’s oral Wegovy weight-loss medication. Novo contended the product violated patents protecting its bestselling treatments.
The legal action represented just one chapter in their ongoing dispute. Novo had previously challenged Hims for allegedly continuing to promote compounded alternatives of its medications following an earlier disagreement.
Michael Cherny from Leerink characterized the development as “both a surprise and an unabashed positive for HIMS’ stock.” He noted the agreement might circumvent what appeared to be “a protracted legal process that could include a full trial.”
However, Cherny refrained from adopting a bullish stance. “Even with this positive news, we do not see this as a clearing event for HIMS to fully recapture its growth potential,” he stated, maintaining a Market Perform rating.
Craig Hettenbach from Morgan Stanley shared a comparable perspective. He indicated the partnership might remove one of the most significant obstacles facing HIMS — the regulatory and legal uncertainties surrounding its weight-loss operations.
Hettenbach noted that “any reduction in those risks could lead to a strong reband in the heavily shorted stock.”
Telehealth platforms like Hims gained the ability to distribute more affordable compounded alternatives of Novo and Eli Lilly weight-loss treatments during supply shortage periods affecting the branded products.
These supply constraints have since been resolved. Regulators anticipated compounding activities would cease, yet certain telehealth providers continued operations by modifying dosages or formulations in attempts to distinguish their offerings from branded alternatives.
This strategy placed Hims in Novo’s legal sights earlier this year.
The newly reported agreement, pending confirmation, would fundamentally transform that dynamic — converting Hims from a rival into a distribution channel for Novo’s medications.
Novo’s Copenhagen-listed shares traded approximately 1% higher on the developments as of early Monday morning.
The post Hims & Hers (HIMS) Stock Rockets 44% on Surprise Novo Nordisk Partnership Deal appeared first on Blockonomi.
